Results 141 to 150 of about 7,486 (163)

Longitudinal changes of serum immunoglobulins under ocrelizumab: factors associated with hypogammaglobulinemia and infection risk in a real-world multiple sclerosis cohort. [PDF]

Neurol Res Pract
Bohn A, Teubner FS, Tauber SC, Waschbisch A.   +3 more
europepmc   +1 more source

Comorbidities in multiple sclerosis: acquired hepatocerebral degeneration mimicking disease progression. [PDF]

Neurol Sci
Einsiedler M, Polymeris A, Raptis N, Beyer A, Becker D, Krassenburg L, Panne I, Mahmutoglu MA, Lieb JM, Rüegg S, Derfuss T, Kuhle J.   +11 more
europepmc   +1 more source

Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review. [PDF]

Br J Clin Pharmacol
Fresse A, Hommel C, Petitpain N, Kerschen P.   +3 more
europepmc   +1 more source

Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis. [PDF]

Neurol Sci
Maal AB, Arki MK, Nabavi SM, Rezaei-Tavirani M, Rismani E, Vosough M, Azizi G, Hossein-Khannazer N.   +7 more
europepmc   +1 more source

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review. [PDF]

J Neurol
Avedillo-Salas A, Martínez LB, Fanlo-Villacampa A, Vicente-Romero J.   +3 more
europepmc   +1 more source

Clinical and Epidemiological Characteristics of Multiple Sclerosis in a Peruvian Cohort: A Retrospective Study Across Three Lima Hospitals. [PDF]

Neurol Int
Cruz AC, Perez-Villegas J, Alvarado E, Smith E, Dueñas-Pacheco I.   +4 more
europepmc   +1 more source

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance. [PDF]

Mult Scler
Mullan G, Ford HL, Blackall P, Bongol D, Bonham N, Brex P, Hoyle N, Murray K, Nelson-Piercy C, Pearson OR, Rog D, Prinja P, Dobson R.   +12 more
europepmc   +1 more source

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Multiple Sclerosis Journal, 2022
Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab.
Raed Alroughani, Mastura Monif, Richard Macdonell   +2 more
exaly   +2 more sources

Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study [PDF]

European Journal of Neurology, 2022
Background and purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited.
Peter V Rasmussen, Stephan Bramow, Viktoria Papp   +2 more
exaly   +2 more sources